A detailed history of Two Sigma Investments, LP transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 218,629 shares of CRDF stock, worth $583,739. This represents 0.0% of its overall portfolio holdings.

Number of Shares
218,629
Previous 22,967 851.93%
Holding current value
$583,739
Previous $122,000 297.54%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.22 - $5.89 $434,369 - $1.15 Million
195,662 Added 851.93%
218,629 $485,000
Q1 2024

May 15, 2024

SELL
$1.46 - $5.91 $11,242 - $45,507
-7,700 Reduced 25.11%
22,967 $122,000
Q4 2023

Feb 14, 2024

SELL
$0.96 - $1.55 $21,696 - $35,030
-22,600 Reduced 42.43%
30,667 $45,000
Q3 2023

Nov 14, 2023

SELL
$1.38 - $2.18 $55,151 - $87,123
-39,965 Reduced 42.87%
53,267 $74,000
Q2 2023

Aug 14, 2023

BUY
$1.37 - $1.95 $86,627 - $123,302
63,232 Added 210.77%
93,232 $137,000
Q1 2023

May 15, 2023

BUY
$1.45 - $2.09 $9,701 - $13,984
6,691 Added 28.71%
30,000 $49,000
Q4 2022

Feb 14, 2023

BUY
$1.22 - $1.66 $28,436 - $38,692
23,309 New
23,309 $32,000
Q2 2022

Aug 15, 2022

SELL
$1.17 - $2.61 $531,563 - $1.19 Million
-454,328 Reduced 97.42%
12,019 $26,000
Q1 2022

May 16, 2022

BUY
$2.11 - $7.25 $187,743 - $645,090
88,978 Added 23.58%
466,347 $1.16 Million
Q4 2021

Feb 14, 2022

SELL
$5.18 - $7.24 $1.18 Million - $1.65 Million
-227,381 Reduced 37.6%
377,369 $2.27 Million
Q3 2021

Nov 15, 2021

SELL
$5.01 - $7.58 $520,629 - $787,698
-103,918 Reduced 14.66%
604,750 $4.03 Million
Q2 2021

Aug 16, 2021

SELL
$6.65 - $10.04 $108,335 - $163,561
-16,291 Reduced 2.25%
708,668 $4.71 Million
Q1 2021

May 17, 2021

BUY
$9.1 - $19.57 $3.51 Million - $7.54 Million
385,277 Added 113.42%
724,959 $6.71 Million
Q4 2020

Feb 16, 2021

BUY
$12.02 - $24.71 $4.08 Million - $8.39 Million
339,682 New
339,682 $6.11 Million

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $116M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.